Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
business model of a shell is to be clean free trading viable stock for a profitable multi million dollar private entity to merge into ...works for me
6 quarterlies 1 annual and update officers list on nev sos not 8 yrs worth like some detractors were saying
obstinant just for the sake of always being the ultimate contrarion?
if elected officials from a public office intervene in any way it is public knowledge and can be referenced and acknowledged as such
as far as soliciting ..megas is soliciting nothing just applauding shareholders efforts
dtc keeps saying global lock stays on cuz they "think" theres still counterfeits out there ??? they refuse to show their records of WHY they say that of course ! maybe Attaway can get them to show some Hard facts instead of this uhhhmmm hey what we say goes crap
fingers crossed :)!!gltusall
nice, succinct and to the point well written molson congrats hopefully they heard what you were tryin to say !!
basically occoms razor megas some whacko genius dr.evil plot to beat the world or brokers overselling and hoping company will fail and go away..????
which has been done and done and still not cleared to trade ..so obviously they werent providing the answer the dtc/sec wanted to hear(to make everything /everyones books jive)
RIIIGGHHTTT o k complying with every demand doesnt count ...okeedokee there einstein have a good one then lol:)
and what happened when he WAS CURRENT w filings???genius HMMM??
yep then just show auth was raised to meet dtc compliance and wham"smoking gun"
all megas has to do is , go in front of the judge and say FINALLY now that i have your attention... iwas filing up to date ,i bowed , begged did everything i was asked to!!and i still couldnt trade maybe clean a little house and look in the mirror andyour own backyard & youll see the f'in problem !!!dtc and its owners pullin out all the stops to get the sec(their bitch) to rid them of their problem god forbid they cant hand out 5 million dollar bonus's for the holiday's this year..lol
well then who could possibly knowthe "implied " share structure after trading is suspended then hundreds of millions allowed to trade? besides the dtc?and the guilty brokers who let the trading continue for 2 weeks after they got the MEMO" basically today's fiasco iis brokers and dtc last attempt ...IN Vain to throw their weight @ to make the sec absolve their f#ckup ONCE again
not for filings my mistake just for shhldrs legal:Posted by: mastaflash Date: Thursday, October 01, 2009 6:52:28 PM
In reply to: wildbill who wrote msg# 123819 Post # of 123844
Not a fund for filings. That is the companies responsibility, and it happen whether you contribute or not to the legal fund.
molsen ...donate to the filing fund and it"will happen guarrannnnnnnteeee
NIHK looks about ready to go nice vol today :)
lol yep ,got kids too :Pjust dont want to give the miscreants anything else to whine about :) glt..us all:) wb
burns aint a senator
mmte agree 100% Van..dubai real estate! awesome potential just a matter of time updating pinkshts and filing?vishay's def got somethin planned for this babyjmho gltyall wb
nubl .055 mmte .0004 possible runners grabbed starter in both:)
does burns not know of this or is he just a a tired carriage horse with blinders on??sheesh
APHY .004 20 mil revs w/300k mkt cap??50mil os ,any vol takes it back to highs of year ago .04
APHY .004 50mil os @ 20 mil revenues any vol it flies
hard assets run 5 pharmacies w@4 mil a year revs each wwwaaayy under radars jmo
GVBP :) New stem cell identification technology could cure breast canc
er ( PR Newswire )
B: New stem cell identification technology could cure breast cancer ( PR Newswir
e )
NEW YORK, Sept 11, 2009 /PRNewswire-FirstCall via COMTEX/ --
(OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), released
important information about its innovative method for destroying breast
cancer cells, using stem cell technology.
GENova's approach is based on cutting-edge technology that enables us to
identify the protein expression in the original cancer stem cells that give
rise to tumors. This ability to identify the molecular markers of these cells
is an important first step in developing new and superior cancer cures, says
John Savin, VP for GENova. "By recognizing the existence of cancer stem
cells, we have taken a great step towards understanding this complex disease.
Now that we know how to identify the unique characteristics of these stem
cells, we can develop cell-specific therapies that can eradicate them --and
thus neutralize breast cancer right at the source."
The key behind GENova's biotechnology is tracing cancer cells to their
origin, the very stem cells from where the first malignant cell arose. Now
that they are identifiable, scientists are developing tailor-made proteins
that are programmed to destroy cancerous cells, whilst leaving the healthy
cells intact. GENova has targeted these bio-engineered proteins for
acquisition into its growing anti-cancer drug pipeline.
In the future, this technology will also enable us to identify healthy stem
cells and then develop, inject, and nurture them in such a way that they can
overcome the malignant cells. Eventually, healthy stem cells will overcome
the sick cells, leaving the patient cured. This novel method for treating
breast cancer is far superior to existing treatments, and is the underpinning
of GENova's IP (Intellectual Property) portfolio.
Development of this important biotechnology would mean a new cure for
cancer, rendering disfiguring mastectomies and harmful radiation therapies
obsolete.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in
the development and commercial licensing of novel therapeutic proteins that
disrupt the advance of life-threatening cancers. The company leverages
cutting-edge research collaborations to achieve breakthroughs in anti-cancer
treatments, and then licenses these patented drug product candidates to Big
Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad
Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com
Forward Looking Statements
This document includes certain statements that may be deemed to be
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical fact, are expected by the Company to be
forward-looking statements. Although GENova believes the expectations
expressed in such forward-looking statements are based on reasonable
assumptions, such statements are not guarantees of future performance and
actual results or developments may differ materially from those in the
forward-looking statements. Factors that could cause actual results to differ
materially from those in forward-looking statements include but are not
limited to the success of the owned intellectual property, the strength of
the patents, continued availability of capital and financing, and general
economic market or business conditions.
SOURCE GENova Biotherapeutics, Inc.
Copyright (C) 2009 PR Newswire. All rights reserved
*** end of story ***
GVBP New stem cell identification technology could cure breast canc
er ( PR Newswire )
B: New stem cell identification technology could cure breast cancer ( PR Newswir
e )
NEW YORK, Sept 11, 2009 /PRNewswire-FirstCall via COMTEX/ --
(OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), released
important information about its innovative method for destroying breast
cancer cells, using stem cell technology.
GENova's approach is based on cutting-edge technology that enables us to
identify the protein expression in the original cancer stem cells that give
rise to tumors. This ability to identify the molecular markers of these cells
is an important first step in developing new and superior cancer cures, says
John Savin, VP for GENova. "By recognizing the existence of cancer stem
cells, we have taken a great step towards understanding this complex disease.
Now that we know how to identify the unique characteristics of these stem
cells, we can develop cell-specific therapies that can eradicate them --and
thus neutralize breast cancer right at the source."
The key behind GENova's biotechnology is tracing cancer cells to their
origin, the very stem cells from where the first malignant cell arose. Now
that they are identifiable, scientists are developing tailor-made proteins
that are programmed to destroy cancerous cells, whilst leaving the healthy
cells intact. GENova has targeted these bio-engineered proteins for
acquisition into its growing anti-cancer drug pipeline.
In the future, this technology will also enable us to identify healthy stem
cells and then develop, inject, and nurture them in such a way that they can
overcome the malignant cells. Eventually, healthy stem cells will overcome
the sick cells, leaving the patient cured. This novel method for treating
breast cancer is far superior to existing treatments, and is the underpinning
of GENova's IP (Intellectual Property) portfolio.
Development of this important biotechnology would mean a new cure for
cancer, rendering disfiguring mastectomies and harmful radiation therapies
obsolete.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in
the development and commercial licensing of novel therapeutic proteins that
disrupt the advance of life-threatening cancers. The company leverages
cutting-edge research collaborations to achieve breakthroughs in anti-cancer
treatments, and then licenses these patented drug product candidates to Big
Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad
Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com
Forward Looking Statements
This document includes certain statements that may be deemed to be
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical fact, are expected by the Company to be
forward-looking statements. Although GENova believes the expectations
expressed in such forward-looking statements are based on reasonable
assumptions, such statements are not guarantees of future performance and
actual results or developments may differ materially from those in the
forward-looking statements. Factors that could cause actual results to differ
materially from those in forward-looking statements include but are not
limited to the success of the owned intellectual property, the strength of
the patents, continued availability of capital and financing, and general
economic market or business conditions.
SOURCE GENova Biotherapeutics, Inc.
Copyright (C) 2009 PR Newswire. All rights reserved
*** end of story ***
APHY .oo4x.0085 now :)
aphy .004 nice vol 56mil os last 10q nov. shows 4mill revs per quarter
trades easy tween .004 .015
yep smart traders ate up the dips ..see how fast it went back to 001 nice
one day opgx 'll do what icbu.0003-009 2800% or hesv .0002-.014 at one point was 8900% :)ps those both were just today uugh!:)
as soon as they buy them back in an open market, aka when the dtc is convinced they can clear themselves of any misappropreations and absolve themselves of any oversight
jmo but i think doms is holdin it down so Oxigene can increase thr holdings on the cheap :)
lol im bettin on the cat... cool pic
youre absolutely right the dtcc did not do that UNKNOWINGLY... they knew EXACTLY what they were doing
"What the DTCC or the DTC or any agency of theirs did not do unknowingly before, they certainly cannot do now either."
double negative proves our point
i dont know nuthin jmho
like the hill wasnt steep at 0005? or 0007?? from a technical stand point this is just a typical 50% retracement after new highs its happened like clockwork several times in the last few weeks jmho bwtfdik :)
thinks hes a PLAYA ..accents gone too lol like his shs make a difference oohh you bought and sold ,ooohhh his mommy will be so proud when she changes his diaper hahahaaa
could someone find out why buzz cloud scroll over doesnt update... its had opgx @ .0004 for a week now thx guys preciate it
wish scroll overfor opgx in buzz cloud would show current instead of .0004
a lot of computers got beat up that day !!